dc.contributor.author | Boon, E | |
dc.contributor.author | van Boxtel, W | |
dc.contributor.author | Buter, J | |
dc.contributor.author | Baatenburg de Jong, RJ | |
dc.contributor.author | van Es, RJJ | |
dc.contributor.author | Bel, M | |
dc.contributor.author | Fiets, E | |
dc.contributor.author | Oosting, SF | |
dc.contributor.author | Slingerland, M | |
dc.contributor.author | Hoeben, A | |
dc.contributor.author | Tesselaar, MET | |
dc.contributor.author | Jonker, MA | |
dc.contributor.author | Flucke, UE | |
dc.contributor.author | Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group | |
dc.contributor.author | van der Graaf, WTA | |
dc.contributor.author | van Herpen, CML | |
dc.date.accessioned | 2017-11-06T12:16:02Z | |
dc.date.issued | 2018-03 | |
dc.identifier.citation | Head & neck, 2018, 40 (3), pp. 605 - 613 | |
dc.identifier.issn | 1043-3074 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/901 | |
dc.identifier.eissn | 1097-0347 | |
dc.identifier.doi | 10.1002/hed.25035 | |
dc.description.abstract | Background Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT).Methods Patients with advanced androgen receptor-positive salivary duct carcinoma treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression-free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care.Results Thirty-four of 35 patients who were ADT-treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT-treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P = .02).Conclusion We recommend ADT in advanced androgen receptor-positive salivary duct carcinoma given its response and clinical benefit. © 2017 Wiley Periodicals, Inc. Head Neck, 2017. | |
dc.format | Print-Electronic | |
dc.format.extent | 605 - 613 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.subject | Nationwide Network and Registry of Histopathology and Cytopathology (PALGA) Group | |
dc.subject | Salivary Ducts | |
dc.subject | Humans | |
dc.subject | Salivary Gland Neoplasms | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Androgen Antagonists | |
dc.subject | Receptors, Androgen | |
dc.subject | Treatment Outcome | |
dc.subject | Registries | |
dc.subject | Survival Rate | |
dc.subject | Retrospective Studies | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Netherlands | |
dc.subject | Female | |
dc.subject | Male | |
dc.title | Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-10-25 | |
rioxxterms.funder | The Institute of Cancer Research | |
rioxxterms.identifier.project | Unspecified | |
rioxxterms.versionofrecord | 10.1002/hed.25035 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2018-03 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Head & neck | |
pubs.issue | 3 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.publication-status | Published | |
pubs.volume | 40 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Clinical and Translational Sarcoma | en_US |
dc.contributor.icrauthor | van der Graaf, Wilhelmina | |